Sinphar Pharmaceutical Co's quarterly market cap
declined
from Jun. 2025 (NT$5,905 Mil) to Sep. 2025 (NT$5,811 Mil) and
declined
from Sep. 2025 (NT$5,811 Mil) to Dec. 2025 (NT$5,801 Mil).
Sinphar Pharmaceutical Co's annual market cap
declined
from Dec. 2023 (NT$5,694 Mil) to Dec. 2024 (NT$5,652 Mil) but then
increased
from Dec. 2024 (NT$5,652 Mil) to Dec. 2025 (NT$5,801 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinphar Pharmaceutical Co's Enterprise Value for Today is NT$7,025 Mil.
Sinphar Pharmaceutical Co (TPE:1734) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinphar Pharmaceutical Co Market Cap Related Terms
Sinphar Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a Market Cap of NT$6,238 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinphar Pharmaceutical Co and its competitors. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #612 out of 1427 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Sinphar Pharmaceutical Co's Market Cap too high?
Sinphar Pharmaceutical Co's current Market Cap is NT$6,238 Mil. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #612 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #612 out of 1427 companies for Market Cap. This puts Sinphar Pharmaceutical Co in the upper half of its industry. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current Market Cap is NT$6,238 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$32.80 — trading 1% below its estimated fair value. The current Market Cap is NT$6,238 Mil. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Market Cap is NT$6,238 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$32.80 is trading 1% below its estimated GF Value™ of NT$33.14.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
Market Cap: NT$6,238 Mil
GF Value™: NT$33.14 vs. price of NT$32.80 (1% below fair value)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
